PFE

Pfizer is a stabilized but no-growth business priced for its problems. Revenue has settled around the low-$60Bs after the COVID boom-bust (FY2022 $101B → FY2023 $59.6B → FY2025 $62.6B, -1.6% YoY), and GAAP earnings, while recovered from the FY2023 trough ($2.12B), slipped again to $7.77B (-3.2%), with diluted EPS of $1.36 (-3.5%). On reported EPS the 18.5x P/E looks unremarkable. The cheapness lives below the GAAP line: management reports Adjusted diluted EPS of $3.22, up 4%, implying roughly 8x adjusted earnings, and with $11.7B operating cash flow against $2.63B capex the business throws off ~$9B of free cash (a ~6% FCF yield on the $143B cap). The gap between $1.36 GAAP and $3.22 adjusted is largely non-cash amortization of acquired intangibles (D&A $6.59B), so the cash-generative core is healthier than headline net margin (12.4%) or ROE (9.0%) suggest.

The risk side is concrete, and the company tells on itself. The MD&A's 2026 priorities — 'Invest to maximize post-2028 growth' — explicitly frame the growth story as a back-half-of-the-decade event, code for the looming loss-of-exclusivity cliff that hangs over the current portfolio; near-term, revenue is flat-to-down and the cost story is doing the heavy lifting (the multi-year cost-realignment and Manufacturing Optimization programs, expanded in 2025 around R&D and SI&A via AI/automation, are why adjusted EPS rose while sales fell). The balance sheet is serviceable but not comfortable: long-term debt rose 7.4% to $61.6B while cash sits at just $1.14B, leaving the company reliant on its ~$9B FCF stream to service debt and fund the dividend (buybacks were $0 in FY2024). Liabilities/equity of 1.40x and a 1.16x current ratio ($42.9B vs $37.0B) are adequate, not strong.